• Citer

HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2

par Hanker, Ariella A.B.;Frampton, Garrett G.M.;Sanford, Eric;Owens, Philip;Becker, Jennifer;Groseclose, Reid M.R.;Castellino, Stephen;Joensuu, Heikki;Huober, Jens;Brase, Jan Christoph;Majjaj, Samira ;Garrett, Joan J.T.;Brohée, Sylvain ;Venet, David ;Brown, David Norman ;Baselga, José;Piccart-Gebhart, Martine ;Sotiriou, Christos ;Arteaga, Carlos C.L.;Estrada, Mónica Valeria;Moore, Preston P.D.;Ericsson, Paula Gonzalez;Koch, James J.P.;Langley, Emma;Singh, Sharat;Kim, Phillip P.S.
Référence Clinical cancer research, 23, 15, page (4323-4334)
Publication Publié, 2017-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2
Auteur:	Hanker, Ariella A.B.; Frampton, Garrett G.M.; Sanford, Eric; Owens, Philip; Becker, Jennifer; Groseclose, Reid M.R.; Castellino, Stephen; Joensuu, Heikki; Huober, Jens; Brase, Jan Christoph; Majjaj, Samira; Garrett, Joan J.T.; Brohée, Sylvain; Venet, David; Brown, David Norman; Baselga, José; Piccart-Gebhart, Martine; Sotiriou, Christos; Arteaga, Carlos C.L.; Estrada, Mónica Valeria; Moore, Preston P.D.; Ericsson, Paula Gonzalez; Koch, James J.P.; Langley, Emma; Singh, Sharat; Kim, Phillip P.S.
Informations sur la publication:	Clinical cancer research, 23, 15, page (4323-4334)
Statut de publication:	Publié, 2017-08
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1078-0432
	info:doi/10.1158/1078-0432.CCR-16-2287
	info:scp/85027131060